Huntington’s disease is a severe neurodegenerative disorder, characterized by its autosomal dominant inheritance pattern. This condition leads to progressive brain degeneration starting in adulthood, resulting in rapid deterioration and eventual death. The Genetic Basis and Symptoms of Huntington’s Disease The disorder is notably classified as the most prevalent among trinucleotide repeat neurodegenerative diseases. It involves […]
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression in Alzheimer’s type dementias. The Indian biopharma company expects to enroll patients from mid-September. Masupirdine is a selective, brain penetrant and orally active, chemical entity. Its late-stage study to be […]
Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in developing disease-modifying AAV9-based gene therapies for neurodegenerative diseases. According to the US pharma giant, the acquisition will set up a new modality for drug discovery and development. It will also […]
Massachusetts-based Yumanity Therapeutics has secured a drug development deal worth up to nearly $500 million with pharma giant Merck to develop new therapies for neurodegenerative disorders. The partnership is set to combine the drug discovery platform of Yumanity Therapeutics with the development and commercialization expertise in neuroscience of Merck. As per the deal, Merck will […]